Phaseline

Targets › PIK3D

PIK3D: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on PIK3D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institute of Hematology & Blood Diseases Hospital, ChinaLinperlisib
PI3K inhibitor
PIK3CA, PIK3CB, PIK3DPhase 2Relapsed/Refractory Large B-Cell Lymphoma; Lymphoma, T-CellDec 2026

Conditions

Relapsed/Refractory Large B-Cell Lymphoma (1) Lymphoma, T-Cell (1)

Modalities

small molecule (1)

Companies

Institute of Hematology & Blood Diseases Hospital, China (1)

Related targets

PIK3CA (1) PIK3CB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.